| Hani Rashid, DO | |
|
9520 W Palm Ln Ste 220, Phoenix, AZ 85037-4403 | |
| (480) 443-8400 | |
| (480) 443-8697 |
| Full Name | Hani Rashid |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 10 Years |
| Location | 9520 W Palm Ln Ste 220, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265842389 | NPI | - | NPPES |
| ZWDBCB05 | Other | AZ | MEDICARE |
| 370693 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 008096 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arizona Arthritis And Rheumatology Associates P C | 8123912516 | 21 |
News Archive
Blood levels of a variant form of the nuclear matrix protein Ciz1 are significantly higher in individuals with early- and late-stage lung cancer than in lung cancer-free individuals, researchers report.
For 40 percent of the estimated six million American couples battling infertility, the problem lies with the man. But help may be on the way.
Doctors and medicine-makers today called for an expected $280 million Pharmaceutical Benefits Scheme (PBS) windfall to be ploughed into bringing down the price of new cancer and HIV drugs.
Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.
› Verified 7 days ago
| Entity Name | Arizona Arthritis & Rheumatology Associates P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366489254 PECOS PAC ID: 8123912516 Enrollment ID: O20040209000235 |
News Archive
Blood levels of a variant form of the nuclear matrix protein Ciz1 are significantly higher in individuals with early- and late-stage lung cancer than in lung cancer-free individuals, researchers report.
For 40 percent of the estimated six million American couples battling infertility, the problem lies with the man. But help may be on the way.
Doctors and medicine-makers today called for an expected $280 million Pharmaceutical Benefits Scheme (PBS) windfall to be ploughed into bringing down the price of new cancer and HIV drugs.
Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hani Rashid, DO 4550 E Bell Rd Ste 170, Phoenix, AZ 85032-9385 Ph: (480) 443-8400 | Hani Rashid, DO 9520 W Palm Ln Ste 220, Phoenix, AZ 85037-4403 Ph: (480) 443-8400 |
News Archive
Blood levels of a variant form of the nuclear matrix protein Ciz1 are significantly higher in individuals with early- and late-stage lung cancer than in lung cancer-free individuals, researchers report.
For 40 percent of the estimated six million American couples battling infertility, the problem lies with the man. But help may be on the way.
Doctors and medicine-makers today called for an expected $280 million Pharmaceutical Benefits Scheme (PBS) windfall to be ploughed into bringing down the price of new cancer and HIV drugs.
Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.
› Verified 7 days ago
Moustafa I Hazin, D.O. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 500 W Thomas Rd, Suite 900, Phoenix, AZ 85013 Phone: 602-406-5590 Fax: 602-406-7165 | |
Dr. Ali Shaheen Al-yaqoobi, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 2601 E Roosevelt St, Phoenix, AZ 85008 Phone: 602-344-5411 | |
Dana Archbold, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1111 E Mcdowell Rd, Phoenix, AZ 85006 Phone: 602-839-2296 Fax: 602-839-2084 | |
Catalina Nicole Flores, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 350 W Thomas Rd Dept Of, Phoenix, AZ 85013 Phone: 602-406-3000 | |
Kristina Yancey, Rheumatology Medicare: Medicare Enrolled Practice Location: 5777 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-342-2000 | |
Dr. Francisco Cordova, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 29 W Edgemont Ave, Phoenix, AZ 85003 Phone: 602-263-8971 Fax: 602-263-8971 | |
Dr. Dimpy Kapoor, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 9305 W Thomas Rd, Ste 455, Phoenix, AZ 85037 Phone: 623-399-9010 Fax: 623-399-9013 |